TITLE

New botulinum toxin approved with REMS

AUTHOR(S)
Thompson, Cheryl A.
PUB. DATE
September 2010
SOURCE
American Journal of Health-System Pharmacy;9/15/2010, Vol. 67 Issue 18, p1486
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that the U.S. Food and Drug Administration (FDA) has approved the incobotulinumtoxinA product, Xeomin, of Merz Pharmaceuticals with a risk evaluation and mitigation strategy (REMS). It is stated that the drug will be used for the treatment of cervical dystonia in adults. The REMS is stated to be a medication guide and a communication plan with a warning that all botulinum toxin products may spread from the injection site.
ACCESSION #
53432557

 

Related Articles

  • FDA actions in brief.  // Formulary;Aug2004, Vol. 39 Issue 8, p390 

    Reports on drugs approved by the U.S. Food and Drug Administration as of August 2004. Johnson & Johnson's Levofloxacin tablets for multi-drug resistant Streptococcus pneumoniae in community-acquired pneumonia; Allergan's intradermal botulinum toxin for the treatment of primary axillary...

  • news briefs.  // Dermatology Times;Sep2010, Vol. 31 Issue 9, p18 

    The article offers medicine-related news briefs. The U.S. Food and Drug Administration (FDA) has given its approval for Xeomin to treat blepharospasm and cervical dystonia in adults. The study conducted by the researchers at the University of Minnesota, Minneapolis reveals that bone marrow...

  • Restylane approval spurs analysis of new treatments. Samalonis, Lisa B. // Cosmetic Surgery Times;Jan2004, Vol. 7 Issue 1, p1 

    Reports on the impact of the approval of the drug Restylane for soft-tissue rejuvenation by the U.S. Food and Drug Administration (FDA) on cosmetic surgery medicine. Effectiveness of removing wrinkles in combination with Botox; Cosmetic uses; Hyaluronic acid; FDA drug restrictions; Mild side...

  • FDA Actions.  // Travel Medicine Advisor;Apr2008, Vol. 18 Issue 4, p2 

    The article presents an update on the activities of the U.S. Food and Drug Administration (FDA) as of April 2008. The agency has approved bevacizumab for first-line treatment of women with metastatic HER2-negative breast cancer. An early communication about the safety review of botulinum toxin...

  • Move over Botox. Melville, Nancy A. // Dermatology Times;Jan2008, Vol. 29 Issue 1, p56 

    The article focuses on new forms of botulinum toxin that will share market with several new neurotoxins that are working their way toward Food and Drug Administration (FDA) approval. It is stated that the leading future competitor for Botox will be Reloxin, another botulinum toxin type A. In...

  • Physician, beware. Jesitus, John // Dermatology Times;Oct2012, Vol. 33 Issue 10, p63 

    The article discusses the importance of FDA drug approval process in the light of rise in numbers of unapproved toxins in other countries. The FDA recently approved Xeomin and its pivotal clinical trials set a more stringent endpoint than the trials of Botox and Dysport. It is suggested that...

  • Allergan Receives FDA Approval for First-of-Its-Kind, Fully in vitro, Cell-Based Assay for BOTOX(r) and BOTOX(r) Cosmetic (onabotulinumtoxinA).  // Biomedical Market Newsletter;6/30/2011, p51 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) on the cell-based assay for BOTOX Cosmetic from Allergan Inc. It states that the approval will be implemented immediately for release of product for sale in the U.S. It mentions that the company predicts that the...

  • FDA Actions.  // Neurology Alert;Apr2008, Vol. 26 Issue 8, p2 

    The article presents updates on the actions taken by the U.S. Food and Drug Administration (FDA) on some drugs. It has approved bevacizumab or Avastin for first-line treatment of women with metastatic HER2-negative breast cancer. An early communication has been also issued about an ongoing...

  • FDA Actions. Elliott, William T. // Primary Care Reports;Apr2008, Vol. 14 Issue 4, p2 

    The article announces the U.S. Food and Drug Administration (FDA) approval of bevacizumab (Avastin) for the treatment of metastatic HER2-negative breast cancer when used in combination with paclitaxel reducing disease progression compared to treatment with paclitaxel alone. The article also...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics